CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop a novel test that predicts individual cancer patient responses to targeted therapies using CRISPR/Cas9 technology. By mimicking drug effects through gene knockout, the approach seeks to identify which patients will benefit from specific anticancer drugs, thereby improving treatment outcomes…
For decades, oncologists treating cancer patients desire biomarkers that predict drug sensitivity on a patient individual level; unfortunately, the challenge remains unsolved until today.
As treating clinicians are unable to identify the patients who benefit most and despite advanced multi-omics diagnostics, the majority of cancer patients are treated according to risk groups.
As a result, patients receive inactive drugs without benefit, but adverse effects and European healthcare systems lose s…
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
